Baylor College of Medicine

Study on Pediatric Remdesivir (H-47889)

Description

Content

A phase 2/3 open-label study to evaluate the safety, tolerability, efficacy and pk of Remdesivir in participants from birth to < 18 years of age with Covid-19.

Contact

Araceli Boan

Phone 1: 713–798–1037

IRB: H-47889

Status:

Active

Created:

Back to topback-to-top